• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by COMPASS Pathways Plc (Amendment)

    2/14/22 4:17:12 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMPS alert in real time by email
    SC 13G/A 1 tm226592d3_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 1)

     

    Under the Securities Exchange Act of 1934

     

    COMPASS Pathways plc

    (Name of Issuer)

     

    Ordinary shares, nominal value £0.008 per share**

    (Title of Class of Securities)

     

    20451W101**

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    xRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    ** CUSIP number 20451W101 has been assigned to the American depositary shares (“ADSs”) of the Issuer, which are quoted on The Nasdaq Stock Market under the symbol “CMPS.” Each ADS represents one Ordinary Share of the Issuer. No CUSIP number has been assigned to the Ordinary Shares of the Issuer.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 20451W101   Page 2 of 10 Pages

     

    1.

    Name of Reporting Persons

     

    Peter Thiel

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

     

    4.

    Citizenship or Place of Organization

     

    United States

     

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With:

     

    5.

    Sole Voting Power

     

    897,378 (1)

    6.

    Shared Voting Power

     

    408,410 (2)

    7.

    Sole Dispositive Power

     

    897,378 (1)

    8.

    Shared Dispositive Power

     

    408,410 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,305,788 (3)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    3.1% (4)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           

    (1) Consists of ordinary shares represented by ADSs of the Issuer held by Rivendell Investments 2017-9 LLC. The reporting person is the sole beneficial owner of Rivendell Investments 2017-9 LLC and may be deemed to beneficially own the shares held by such limited liability company.

     

    (2) Consists of ordinary shares represented by ADSs of the Issuer beneficially owned by The Founders Fund VII Management, LLC. The reporting person is a managing member of The Founders Fund VII Management, LLC and shares voting and dispositive power over such shares.

     

    (3) Includes the amounts set forth under footnotes (1) and (2) above.

     

    (4) This percentage is calculated pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), based upon 41,731,180 outstanding ordinary shares of the Issuer as of September 30, 2021, as reported in the Issuer’s report on Form 6-K, as filed with the Securities and Exchange Commission on November 9, 2021.

     

     

     

     

    CUSIP No. 20451W101   Page 3 of 10 Pages

     

    1.

    Name of Reporting Persons

     

    The Founders Fund VII, LP

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With:

     

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    361,863

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    361,863

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    361,863

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ¨ 

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    0.9% (1)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           

    (1) This percentage is calculated pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), based upon 41,731,180 outstanding ordinary shares of the Issuer as of September 30, 2021, as reported in the Issuer’s report on Form 6-K, as filed with the Securities and Exchange Commission on November 9, 2021.

     

     

     

     

    CUSIP No. 20451W101   Page 4 of 10 Pages

     

    1.

    Name of Reporting Persons

     

    The Founders Fund VII Entrepreneurs Fund, LP

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With:

     

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    3,184

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    3,184

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,184

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨ 

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    0.0% (1)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           

    (1) This percentage is calculated pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), based upon 41,731,180 outstanding ordinary shares of the Issuer as of September 30, 2021, as reported in the Issuer’s report on Form 6-K, as filed with the Securities and Exchange Commission on November 9, 2021.

     

     

     

     

    CUSIP No. 20451W101   Page 5 of 10 Pages

     

    1.

    Name of Reporting Persons

     

    The Founders Fund VII Principals Fund, LP

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With:

     

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    43,363

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    43,363

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    43,363

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ¨ 

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    0.1% (1)

    12.

    Type of Reporting Person (See Instructions)

     

    PN

           

    (1) This percentage is calculated pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), based upon 41,731,180 outstanding ordinary shares of the Issuer as of September 30, 2021, as reported in the Issuer’s report on Form 6-K, as filed with the Securities and Exchange Commission on November 9, 2021.

     

     

     

     

    CUSIP No. 20451W101   Page 6 of 10 Pages

     

    1.

    Name of Reporting Persons

     

    The Founders Fund VII Management, LLC

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With:

     

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    408,410 (1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    408,410 (1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    408,410 (1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨ 

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.0% (2)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

    (1) Consists of ordinary shares represented by ADSs of the Issuer held by The Founders Fund VII, LP, The Founders Fund VII Entrepreneurs Fund, LP and The Founders Fund VII Principals Fund, LP. The reporting person is the general partner of these partnerships and may be deemed to beneficially own the shares held by such partnerships.

     

    (2)This percentage is calculated pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), based upon 41,731,180 outstanding ordinary shares of the Issuer as of September 30, 2021, as reported in the Issuer’s report on Form 6-K, as filed with the Securities and Exchange Commission on November 9, 2021.

     

     

     

     

    CUSIP No. 20451W101   Page 7 of 10 Pages

     

    1.

    Name of Reporting Persons

     

    Rivendell Investments 2017-9 LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of

     

    Shares

     

    Beneficially

     

    Owned by

     

    Each

     

    Reporting

     

    Person With:

     

    5.

    Sole Voting Power

     

    897,378

    6.

    Shared Voting Power

     

    0

    7.

    Sole Dispositive Power

     

    897,378

    8.

    Shared Dispositive Power

     

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    897,378

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨ 

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    2.2% (1)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

    (1) This percentage is calculated pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), based upon 41,731,180 outstanding ordinary shares of the Issuer as of September 30, 2021, as reported in the Issuer’s report on Form 6-K, as filed with the Securities and Exchange Commission on November 9, 2021.

     

     

     

     

    CUSIP No. 20451W101   Page 8 of 10 Pages

     

    Item 1(a)Name of Issuer

     

    COMPASS Pathways plc

     

    Item 1(b)Address of Issuer's Principal Executive Offices

     

    3rd Floor

    1 Ashley Road

    Altrincham

    Cheshire WA14 2DT

    United Kingdom

     

    Item 2(a)Name of Person Filing

     

    This Statement on Schedule 13G has been filed on behalf of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”):

     

    1.Peter Thiel
    2.The Founders Fund VII, LP
    3.The Founders Fund VII Entrepreneurs Fund, LP
    4.The Founders Fund VII Principals Fund, LP
    5.The Founders Fund VII Management, LLC
    6.Rivendell Investments 2017-9 LLC

     

    Item 2(b)Address of Principal Business Office or, if none, Residence

     

    The address of Mr. Thiel is:

    c/o Thiel Capital LLC

    9200 Sunset Boulevard, Suite 1110

    West Hollywood, California 90069

     

    The address of Rivendell Investments 2017-9 LLC is:

    1209 Orange Street,

    Wilmington, DE 19801

     

    The address of each other Reporting Person is:

     

    c/oThe Founders Fund

    One Letterman Drive Building D, Suite 500

    San Francisco, California 94129

     

    Item 2(c)Citizenship

     

    1.Peter Thiel is a United States citizen
    2.The Founders Fund VII, LP is organized in Delaware
    3.The Founders Fund VII Entrepreneurs Fund, LP is organized in Delaware
    4.The Founders Fund VII Principals Fund, LP is organized in Delaware
    5.The Founders Fund VII Management, LLC is organized in Delaware
    6.Rivendell Investments 2017-9 LLC is organized in Delaware

     

    Item 2(d)Title of Class of Securities

     

    Ordinary shares, nominal value £0.008 per share

     

    Item 2(e)CUSIP Number

     

    20451W101

     

    The CUSIP number 20451W101 has been assigned to the American depositary shares (“ADSs”) of the Issuer, which are quoted on The Nasdaq Stock Market under the symbol “CMPS.” Each ADS represents one Ordinary Share of the Issuer. No CUSIP number has been assigned to the Ordinary Shares of the Issuer.

     

     

     

     

    CUSIP No. 20451W101   Page 9 of 10 Pages

     

    Item 3 

     

    Not applicable.

     

    Item 4Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1

     

    (a) Amount beneficially owned: See Row 9 of pages 2-7

     

    (b) Percent of class: See Row 11 of pages 2-7

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote: See Row 5 of pages 2-7

    (ii) Shared power to vote or to direct the vote: See Row 6 of pages 2-7

    (iii) Sole power to dispose or to direct the disposition of: See Row 7 of pages 2-7

    (iv) Shared power to dispose or to direct the disposition of: See Row 8 of pages 2-7

     

    Item 5Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. x

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

     

    Not applicable.

     

    Item 8Identification and Classification of Members of the Group

     

    The Reporting Persons are filing this Schedule 13G jointly, but not as members of a group, and each expressly disclaims membership in a group.

     

    Item 9Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10Certification

     

    Not applicable.

     

     

     

     

    CUSIP No. 20451W101   Page 10 of 10 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

      /s/Peter Thiel  
      Peter Thiel 

     

      The Founders Fund VII, LP
      The Founders Fund VII Entrepreneurs Fund, LP
      The Founders Fund VII Principals Fund, LP
      By: The Founders Fund VII Management, LLC
      Their: General Partner
      By: /s/ Peter Thiel
      Name: Peter Thiel
      Title:  Managing Member

     

      The Founders Fund VII Management, LLC
      By: /s/ Peter Thiel
      Name: Peter Thiel
      Title:  Managing Member

     

      Rivendell Investments 2017-9 LLC
      By: /s/ Peter Thiel
      Name: Peter Thiel
      Title:  Authorized Signatory

     

    EXHIBITS

     

    A: Joint Filing Agreement (previously filed and incorporated by reference)

     

     

     

    Get the next $CMPS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMPS

    DatePrice TargetRatingAnalyst
    2/27/2025$11.00Buy
    Stifel
    7/23/2024$23.00Outperform
    RBC Capital Mkts
    4/1/2024$30.00Overweight
    Morgan Stanley
    12/12/2023$16.00Buy
    Deutsche Bank
    11/21/2022$33.00Buy
    Berenberg
    11/1/2022$34.00Buy
    Loop Capital
    11/22/2021$100.00 → $120.00Buy
    HC Wainwright & Co.
    10/29/2021$50.00Outperform
    Oppenheimer
    More analyst ratings

    $CMPS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

      Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20th, 2025. A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We

      5/14/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

      Highlights: 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June Phase 3 COMP006 in TRD on track for 26-week data second half of 2026 Cash position of $260.1 million at March 31, 2025 Conference call on May 8 at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update on recent progress across its business. "We eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal

      5/8/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

      Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR

      4/29/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on COMPASS Pathways with a new price target

      Stifel initiated coverage of COMPASS Pathways with a rating of Buy and set a new price target of $11.00

      2/27/25 6:17:48 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on COMPASS Pathways with a new price target

      RBC Capital Mkts initiated coverage of COMPASS Pathways with a rating of Outperform and set a new price target of $23.00

      7/23/24 6:23:14 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on COMPASS Pathways with a new price target

      Morgan Stanley initiated coverage of COMPASS Pathways with a rating of Overweight and set a new price target of $30.00

      4/1/24 7:29:23 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Financials

    Live finance-specific insights

    See more
    • Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

      Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pathways website at: First Quarter 2025 Financial Results. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is

      4/28/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

      Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter 2024 ending December 31, 2024, and provide an update on recent developments, on February 27th, 2025. Compass management will host a conference call at 8:00 am ET (1:00pm UK) on February 27, 2025. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on the Compass Pathways website at: F

      2/18/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

      Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point, expected in the second half of 2026 Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30% Cash position of $207 million Conference call October 31 at 8:00 am ET (12:00 pm UK) Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progres

      10/31/24 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by COMPASS Pathways Plc

      SCHEDULE 13G - COMPASS Pathways plc (0001816590) (Subject)

      5/15/25 8:00:10 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COMPASS Pathways Plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - COMPASS Pathways plc (0001816590) (Filer)

      5/8/25 6:39:09 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by COMPASS Pathways Plc

      10-Q - COMPASS Pathways plc (0001816590) (Filer)

      5/8/25 6:38:40 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

      SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

      11/14/24 4:35:16 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by COMPASS Pathways Plc

      SC 13G/A - COMPASS Pathways plc (0001816590) (Subject)

      11/14/24 4:20:24 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by COMPASS Pathways Plc

      SC 13G - COMPASS Pathways plc (0001816590) (Subject)

      4/11/24 4:04:21 PM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Leadership Updates

    Live Leadership Updates

    See more
    • Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

      Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in underserved communities, if FDA approved. This agreement with HealthPort expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with treatment resistant depression (TR

      4/29/25 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways appoints Lori Englebert as Chief Commercial Officer

      New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatmentLatest of several key executive team hires, rounding out team to take Compass through phase 3 and beyond LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Lori Englebert as Chief Commercial Officer, effective July 8, 2024. She will be based in the company's New York City office. Lori brings multifaceted experience in global ph

      6/26/24 6:30:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Compass Pathways appoints Teri Loxam as Chief Financial Officer

      LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO.  Teri brings to Compass deep and extensive strategic experience working for publicly traded companies, in the pharmaceutical and biotechnology sectors, and beyond. She joins the company from Gameto, where she was CFO and played a

      12/7/23 7:00:00 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Goodwin Guy

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      3/13/25 8:15:58 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Loxam Teri was granted 25,000 units of Ordinary Shares, increasing direct ownership by 43% to 83,250 units (SEC Form 4)

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      3/13/25 8:15:29 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Nath Kabir was granted 92,000 units of Ordinary Shares, increasing direct ownership by 68% to 227,668 units (SEC Form 4)

      4 - COMPASS Pathways plc (0001816590) (Issuer)

      3/13/25 8:14:56 AM ET
      $CMPS
      Biotechnology: Pharmaceutical Preparations
      Health Care